science wire

« BACK

Pharmacology



Results 401 - 450 of 1331.
« Previous 1 ... 5 6 7 8 9 10 11 12 13 ... 27 Next »


Health - Pharmacology - 16.01.2018
Novartis new data reinforces superiority of Cosentyx versus Stelara * in achieving skin clearance for psoriasis patients
Results from CLARITY study show Cosentyx (secukinumab) was significantly more effective than Stelara * (ustekinumab) in delivering clear and almost clear skin at 12 weeks and at 16 weeks Data support findings from the CLEAR study, which found Cosentyx was superior to Stelara * in achieving sustained skin clearance (PASI 90) at 52 weeks Cosentyx is the first and only fully human interleukin-17A (IL-17A) inhibitor that showed sustained skin cleara

Business / Economics - Pharmacology - 11.01.2018

Pharmacology - Health - 09.01.2018
Novartis advances head-to-head superiority trials of Cosentyx versus Humira * and proposed biosimilar adalimumab**
SURPASS is the first†head-to-head superiority trial versus proposed biosimilar adalimumab** in ankylosing spondylitis†(AS) EXCEED is the first†head-to-head superiority trial versus Humira * in†psoria

Health - Pharmacology - 04.01.2018
Roche launches the cobas Plasma Separation Card to increase access to HIV testing for patients living in remote areas
New technology allows better testing and monitoring of HIV patients living in remote settings For the first time, patient plasma samples no longer need refrigeration during transport to the lab Card

Health - Pharmacology - 04.01.2018
Novartis drug Promacta receives FDA Breakthrough Therapy designation for first-line use in severe aplastic anemia (SAA)
Data supporting designation showed over half of treatment-naÔve SAA patients achieved complete response with Promacta when given with standard immunosuppressive therapy, with overall response rate of

Pharmacology - Health - 03.01.2018
Novartis Kisqali received FDA Breakthrough Therapy designation for initial endocrine-based treatment in premenopausal women with HR+/HER2- advanced breast cancer
Novartis Kisqali received FDA Breakthrough Therapy designation for initial endocrine-based treatment in premenopausal women with HR+/HER2- advanced breast cancer Designation based on Phase III MONALEESA-7 results demonstrating superior efficacy of Kisqali in combination with oral endocrine therapy compared to oral endocrine therapy in preor perimenopausal women who received no prior endocrine therapy for advanced disease Treatment benefit with K

Pharmacology - Health - 22.12.2017
Novartis’ combination therapy Tafinlar + Mekinist granted FDA Priority Review for the adjuvant treatment of stage III BRAF V600 mutation-positive melanoma
Novartis' combination therapy Tafinlar + Mekinist granted FDA Priority Review for the adjuvant treatment of stage III BRAF V600 mutation-positive melanoma Priority Review designation based on Phase I

Pharmacology - Health - 22.12.2017
Novartis drug Tasigna is approved by FDA as first and only CML therapy with Treatment-free Remission data in its label
Inclusion of Treatment-free Remission (TFR) data provides additional and novel option in management of Ph+ CML-CP † Deep and sustained molecular response included as key eligibility criteria for atte

Pharmacology - Health - 21.12.2017
European Commission approves Roche’s Alecensa (alectinib) as first-line treatment in ALK-positive lung cancer
European Commission approves Roche's Alecensa (alectinib) as first-line treatment in ALK-positive lung cancer Alecensa provides a new treatment option for people with newly diagnosed ALK-positive NSC

Pharmacology - Health - 12.12.2017
Roche announces phase III data showing Venclexta/Venclyxto plus MabThera/Rituxan reduced the risk of disease progression or death by 83% compared to a standard of care regimen in previously treated chronic lymphocytic leukaemia
Roche announces phase III data showing Venclexta/Venclyxto plus MabThera/Rituxan reduced the risk of disease progression or death by 83% compared to a standard of care regimen in previously treated c

Health - Pharmacology - 11.12.2017
Using 3D cell cultures to fight anti-cancer therapy resistance
Using 3D cell cultures to fight anti-cancer therapy resistance
An international research team headed by the University of Bern and the Netherlands Cancer Institute has developed 3D cell cultures in which genes can be specifically modified. They allow the study of genes that may cause therapy resistance in breast cancer. This knowledge may further improve the use of targeted anti-cancer drugs.

Health - Pharmacology - 10.12.2017
Primary analysis results from Novartis pivotal JULIET trial show Kymriah(TM) (tisagenlecleucel) sustained complete responses at six months in adults with r/r DLBCL, a difficult-to-treat cancer
Primary analysis results from Novartis pivotal JULIET trial show Kymriah(TM) (tisagenlecleucel) sustained complete responses at six months in adults with r/r DLBCL, a difficult-to-treat cancer At six

Pharmacology - Health - 07.12.2017
Phase III IMpower150 study showed Tecentriq (atezolizumab) and Avastin (bevacizumab) plus chemotherapy reduced the risk of disease worsening or death by 38 percent for people with a type of advanced lung cancer
Phase III IMpower150 study showed Tecentriq (atezolizumab) and Avastin (bevacizumab) plus chemotherapy reduced the risk of disease worsening or death by 38 percent for people with a type of advanced lung cancer First Phase III combination trial of a cancer immunotherapy to show improvement in progression-free survival as an initial treatment in advanced non-squamous non-small-cell lung cancer (NSCLC) Roche today announced results from the positi

Health - Pharmacology - 06.12.2017
Novartis Kisqali is first and only CDK4/6 inhibitor to show superior median PFS compared to oral endocrine therapy as first-line treatment in a prospective, randomized Phase III trial dedicated to
Novartis Kisqali is first and only CDK4/6 inhibitor to show superior median PFS compared to oral endocrine therapy as first-line treatment in a prospective, randomized Phase III trial dedicated to..

Health - Pharmacology - 06.12.2017
Personalized Health: National Funding for Basel-led Research Groups
Personalized Health: National Funding for Basel-led Research Groups
Nine research projects involving Basel-based researchers in the field of personalized health are to receive funding from the Swiss government: support will be given to researchers from the University

Health - Pharmacology - 05.12.2017
Great success for Bern as a medical center
The Swiss Personalized Health Network (SPHN) supports nine research projects with Bernese investment, which aim to build up a nationally coordinated infrastructure of health data.

Health - Pharmacology - 30.11.2017
Novartis’ Cosentyx is first biologic to show long-term efficacy in nail and palmoplantar psoriasis, which can impact up to 90% of psoriasis patients
Novartis' Cosentyx is first biologic to show long-term efficacy in nail and palmoplantar psoriasis, which can impact up to 90% of psoriasis patients Unique Cosentyx (secukinumab) data reinforce treatment option for up to 90% of psoriasis patients who may develop nail or palmoplantar psoriasis - Cosentyx results represent the first data on biologic use for up to 2.5 years in these hard-to-treat types of psoriasis , Results add to body of e

Pharmacology - Health - 29.11.2017
Novartis announces Phase III STRIVE data published in NEJM demonstrating significant and sustained efficacy of erenumab in migraine prevention
Novartis announces Phase III STRIVE data published in NEJM demonstrating significant and sustained efficacy of erenumab in migraine prevention Patients with episodic migraine taking erenumab reported

Health - Pharmacology - 27.11.2017
Novartis’ Ultibro Breezhaler significantly improved COPD patients’ lung function after direct switch from Seretide
† New data showed switching moderate-to-severe, symptomatic COPD patients from Seretide * †to Ultibro †Breezhaler †improved lung function and was well tolerated. † The FLASH study is the first randomized controlled trial to investigate the direct switch of patients from steroid-containing Seretide to the dual bronchodilator Ultibro†Breezhaler.

Psychology - Pharmacology - 27.11.2017
Self-Help Book Works to Combat Burnout and Stress - Without a Therapist
Self-Help Book Works to Combat Burnout and Stress - Without a Therapist
Around a third of all employees find their work stressful. Interventions for stress and burnout are available, but often not accessible for many employees. A self-help book based on Acceptance and Commitment Therapy (ACT) has the potential to reduce burnout, stress and symptoms of depression - without any therapist contact.

Health - Pharmacology - 15.11.2017
Novartis, ASCP and ACS join forces to fight cancer in Ethiopia, Uganda and Tanzania
Objective is to provide patients with rapid cancer diagnostics and appropriate care First focus will be on Ethiopia, Uganda and Tanzania Cancer is on the rise in Africa, with more than 500,000 deaths

Health - Pharmacology - 14.11.2017

Pharmacology - Health - 14.11.2017
New data reinforces clinical basis for switching to Sandoz biosimilar medicines
Sandoz strengthens position as global leader in biosimilars with new immunology data from four clinical studies for proposed biosimilars adalimumab and rituximab Efficacy and safety of biosimilar adalimumab and safety of biosimilar rituximab match reference medicines in multiple-switching and retreatment study respectively† Sandoz biosimilar adalimumab is under EMA review, while EC-approved Sandoz biosimilar rituximab is under review by the FDA

Pharmacology - Health - 14.11.2017
Novartis presents new data at SABCS across broad range of breast cancer patient populations, combination treatments and lines of therapy
Presentation of results from the Kisqali (ribociclib) MONALEESA-7 Phase III trial exclusively studying premenopausal women with HR+/HER2- advanced breast cancer† New MONALEESA-2 analyses focused on q

Health - Pharmacology - 13.11.2017
Novartis canakinumab (ACZ885) reduced cardiovascular risk by 25% in subgroup of CANTOS Phase III trial participants
Subgroup of patients had a 25% reduction in major adverse cardiovascular events when treated with canakinumab in a new analysis of Phase III CANTOS trial presented at the American Heart Association Scientific Sessions 2017   The analysis showed a 31% reduction in cardiovascular death and a 31% reduction in all-cause mortality in patients whose inflammation - as measured by hsCRP - decreased below 2mg/L three months after initiating canakinumab

Health - Pharmacology - 13.11.2017
Novartis highlights its differentiated late stage pipeline at the R&D update and investor event
RTH258 demonstrates superiority versus aflibercept in key secondary endpoint measures of disease activity and meets primary endpoint of non-inferiority in patients with nAMD   AMG 334 has a robust data package, even in difficult to treat patients, and is on track to be the first CGRP to market for treatment of patients with chronic or episodic migraine   Cosentyx has strong differentiation based on its unique biology, which has been proven to

Health - Pharmacology - 12.11.2017
New Novartis Entresto real world evidence data shows beneficial impact on quality of life in people living with heart failure
Entresto reversed trend of worsening New York Heart Association (NYHA) class - a key measure of the severity of a patient's heart failure symptoms - improving common physical activity such as exercise and other daily activities at 90 and 180 days after treatment initiation in a retrospective database study in patients with heart failure with reduced ejection fraction (HFrEF) in Germany Entresto significantly reduced levels of NT-proBNP, a key bl

Health - Pharmacology - 11.11.2017
Punjab province in Pakistan signs agreement with Novartis Access against chronic diseases
Poor patients in Punjab will have access to high-quality  medicines against noncommunicable, chronic diseases thanks to agreement between government and Novartis Access Punjab government will make m

Health - Pharmacology - 10.11.2017
Use of antibiotics - only if necessary
Bern, 10.11.2017 - Spearheading the fight against antimicrobial resistance, the World Health Organization (WHO) launched its Antibiotic Awareness Week.

Pharmacology - Health - 10.11.2017
Novartis brolucizumab (RTH258) demonstrates superiority versus aflibercept in key secondary endpoint measures of disease activity in nAMD, a leading cause of blindness
Novartis brolucizumab (RTH258) demonstrates superiority versus aflibercept in key secondary endpoint measures of disease activity in nAMD, a leading cause of blindness Brolucizumab, the first and only anti-VEGF to maintain a majority of patients on a 12-week treatment schedule immediately following loading phase in Phase III trials, met primary endpoint of non-inferiority vs aflibercept   Significantly fewer brolucizumab patients showed signs o

Health - Pharmacology - 08.11.2017
Novartis reports positive results from Phase III trial of Kisqali (ribociclib) combination therapy in premenopausal women with HR+/HER2- advanced or metastatic breast cancer
Novartis reports positive results from Phase III trial of Kisqali (ribociclib) combination therapy in premenopausal women with HR+/HER2- advanced or metastatic breast cancer MONALEESA-7 met primary e

Health - Pharmacology - 07.11.2017
FDA approves Zelboraf (vemurafenib) for Erdheim-Chester disease with BRAF V600 mutation
FDA approves Zelboraf (vemurafenib) for Erdheim-Chester disease with BRAF V600 mutation Zelboraf is the first FDA-approved treatment for Erdheim-Chester disease (ECD), a rare blood disease Approval based on data from a basket study, which enrolls participants across multiple diseases based predominantly on genetic profile Roche announced today that the US Food and Drug Administration (FDA) has approved Zelboraf (vemurafenib) for Erdheim-Chester disease (ECD) with BRAF V600 mutation.

Pharmacology - Health - 07.11.2017
Novartis announces study data demonstrating Cosentyx reduced signs and symptoms of psoriatic arthritis while inhibiting progression of joint structural damage
Novartis announces study data demonstrating Cosentyx reduced signs and symptoms of psoriatic arthritis while inhibiting progression of joint structural damage Structural joint damage in psoriatic art

Health - Pharmacology - 06.11.2017
Novartis reaches another regulatory milestone for CTL019 (tisagenlecleucel) with submission of its MAA* to EMA for children, young adults with r/r B-cell ALL and adult patients with r/r DLBCL
Novartis reaches another regulatory milestone for CTL019 (tisagenlecleucel) with submission of its MAA* to EMA for children, young adults with r/r B-cell ALL and adult patients with r/r DLBCL Applica

Health - Pharmacology - 06.11.2017
Novartis seeks leadership with Cosentyx showing no radiographic progression in ankylosing spondylitis at 4 years
For the first time for any biologic, data show almost 80 percent of ankylosing spondylitis (AS) patients on Cosentyx have no radiographic progression of the spine at 4 years These new data also confirm sustained improvement in signs and symptoms in almost 80 percent of patients, with a favorable and consistent safety profile Cosentyx, the only IL-17A inhibitor approved for AS, is a fully human, highly targeted biologic for first-line use in this

Pharmacology - Life Sciences - 02.11.2017
Novartis and Amgen announce expanded collaboration with Banner Alzheimer’s Institute in pioneering prevention program
Parties to collaborate on a new Generation Study 2, assessing whether investigational drug CNP520 can prevent or delay the symptoms of Alzheimer's disease (AD)   Clinical trial is part of the Generation Program, which includes cognitively healthy people at genetic risk of developing AD   Generation Study 2 aims to include a broader high-risk population, as compared to the ongoing Generation Study 1        44 million people globally are e

Pharmacology - Health - 01.11.2017
Roche to present new data across a range of blood diseases at the American Society of Hematology (ASH) 2017 Annual Meeting
Roche to present new data across a range of blood diseases at the American Society of Hematology (ASH) 2017 Annual Meeting Further results from emicizumab phase III studies in people with haemophilia

Pharmacology - Health - 01.11.2017
Novartis presents data at ASH for patients with serious blood disorders like lymphoma, leukemia and sickle cell disease
Primary results of pivotal Kymriah TM Phase II JULIET study in relapsed/refractory DLBCL † Post-hoc sub-analysis of crizanlizumab (SEG101, formerly SelG1) SUSTAIN trial evaluating time to first sickl

Health - Pharmacology - 31.10.2017
Novartis submits application to FDA for KymriahTM (tisagenlecleucel) in adult patients with r/r DLBCL, seeking second indication for first-ever FDA approved CAR-T therapy
Novartis submits application to FDA for KymriahTM (tisagenlecleucel) in adult patients with r/r DLBCL, seeking second indication for first-ever FDA approved CAR-T therapy Submission based on updated

Pharmacology - Health - 30.10.2017
Novartis announces the planned acquisition of Advanced Accelerator Applications to strengthen oncology portfolio
Novartis to acquire Advanced Accelerator Applications pending outcome of tender offer and works council consultation † Acquisition would add Lutathera , a first-in-class RadioLigand Therapy (RLT) app

Health - Pharmacology - 30.10.2017
Novartis to present first of its kind evidence for Cosentyx on potential to maintain mobility in patients with AS and PsA
Long-term 4-year data in ankylosing spondylitis (AS) and 24-weeks data in psoriatic arthritis (PsA) to be presented at the 2017 ACR/ARHP Annual Meeting , † Structural disease progression is a major c

Pharmacology - Health - 28.10.2017
Novartis PARADIGMS data show children and adolescents with MS had an 82% lower relapse rate with Gilenya vs. interferon beta-1a
PARADIGMS data also show patients treated with Gilenya had significantly fewer new brain lesions vs.

Pharmacology - Health - 27.10.2017
Sandoz proposed biosimilar pegfilgrastim accepted by EMA for regulatory review
Comprehensive data package demonstrates that Sandoz biosimilar pegfilgrastim matches the reference biologic in terms of safety, efficacy and quality Pegfilgrastim is a long-acting version of oncology

Pharmacology - Health - 25.10.2017
Novartis confirms leadership in multiple sclerosis (MS) with scientific advancements and new data presented at ECTRIMS
Full data from the pivotal Phase III PARADIGMS study of Gilenya (fingolimod) in pediatric MS will be presented for the first time † With 54 accepted abstracts, Novartis presence spans from new siponimod (BAF312) data in secondary progressive MS (SPMS) to innovative research on neurofilaments - a promising MS biomarker - Novartis today announced it will present 54 scientific abstracts from across its multiple sclerosis (MS) research portfolio at

Pharmacology - Business / Economics - 24.10.2017
Novartis delivered growth on top and bottom line in all divisions in Q3
Net sales grew 2% (cc , +2% USD), with growth in all divisions: Cosentyx (USD 556 million, +83% cc) showed strong growth across all indications Entresto (USD 128 million, +138% cc) grew driven by imp

Health - Pharmacology - 23.10.2017
Novartis combination adjuvant therapy Tafinlar + Mekinist receives FDA Breakthrough Therapy Designation for stage III BRAF V600 mutation-positive melanoma patients
Novartis combination adjuvant therapy Tafinlar + Mekinist receives FDA Breakthrough Therapy Designation for stage III BRAF V600 mutation-positive melanoma patients Breakthrough Therapy Designation ba
« Previous 1 ... 5 6 7 8 9 10 11 12 13 ... 27 Next »

This site uses cookies and analysis tools to improve the usability of the site. More information. |